Celldex Biotechnology (NASDAQ: CBIO) filed its second quarter 2026 financial disclosure on July 30, 2026, covering the period ending June 30, 2026. The filing reveals the company's capital structure, equity transactions, and warrant arrangements following its recent business combination and financing activities. Investors are monitoring the company's cash position and ongoing development pipeline as it navigates post-merger operations.

Key Points

  • NASDAQ: CBIO
  • Company filed second quarter 2026 disclosure on July 30, 2026, covering the six-month period ended June 30, 2026
  • Capital structure includes Series Seed Convertible Preferred Stock, Series A Preferred Stock, common stock, pre-funded warrants, and convertible notes
  • Filing documents recent equity issuances and warrant arrangements related to pre-merger and PIPE financing activities completed in June and December 2025

Capital Structure Changes From Recent Transactions

The filing discloses significant changes to Celldex Biotechnology's equity structure resulting from transactions completed in 2025. The company's capital structure now includes Series Seed Convertible Preferred Stock, Series A Preferred Stock, common stock, pre-funded warrants, and convertible notes payable. The disclosure documents financing activities that occurred in June 2025, including issuances of common stock, pre-funded warrants, and convertible notes. A separate PIPE financing transaction is documented as occurring on December 4, 2025, involving additional common stock and pre-funded warrant issuances. These transactions reflect the company's efforts to strengthen its financial position during its transition period.

Convertible Notes and Warrant Arrangements

The filing demonstrates ongoing use of convertible debt instruments and warrant arrangements. The company maintains convertible notes payable with references to a convertible note purchase agreement dating to October 2024. Pre-funded warrants are documented across multiple issuance dates, with activity recorded through the first half of 2026. The filing indicates these instruments represent part of the company's capital structure as of June 30, 2026. The specific terms, conversion rates, and exercise prices for these instruments appear detailed in the underlying transaction documents referenced in the filing, though the reader should consult the complete disclosure for comprehensive terms.

Stock Equity Plans and Employee Compensation

The disclosure reveals the company maintains multiple equity incentive arrangements for employees. Referenced plans include a 2024 Equity Incentive Plan, a 2025 Stock Incentive Plan approved on June 5, 2025, a 2025 Employment Inducement Incentive Award Plan established on October 30, 2025, and a 2025 Employee Stock Purchase Plan effective May 11, 2025. These plans support restricted stock, stock options, and restricted stock unit grants to employees. The filing documents activity in these plans during the first half of 2026, indicating ongoing equity compensation activities. The specific terms, vesting schedules, and outstanding share quantities appear elsewhere in the complete filing documentation.

Fair Value Measurement and Financial Position

The filing includes fair value accounting disclosures distinguishing Level 1, Level 2, and Level 3 inputs as of both June 30, 2026, and December 31, 2025. These measurements apply to warrant liabilities and other financial instruments carried at fair value. The company did not disclose specific asset or liability amounts in this excerpt. Investors monitoring Celldex Biotechnology's financial condition should review the complete balance sheet and valuation footnotes included in the full quarterly filing to assess cash position, liquidity, and total stockholders' equity.